SRR934890
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 41.55716162943495
- age_years
- 34
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.549
- G2M_CHECKPOINT+0.535
- MYC_TARGETS_V1+0.494
- MYC_TARGETS_V2+0.475
- ANGIOGENESIS+0.380
- UNFOLDED_PROTEIN_RESPONSE+0.340
- WNT_BETA_CATENIN_SIGNALING+0.334
- MTORC1_SIGNALING+0.301
- MITOTIC_SPINDLE+0.272
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.268
Top 10 suppressed
- KRAS_SIGNALING_DN-0.378
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.335
- INTERFERON_ALPHA_RESPONSE-0.198
- APICAL_SURFACE-0.178
- MYOGENESIS-0.155
- HEME_METABOLISM-0.137
- BILE_ACID_METABOLISM-0.136
- ESTROGEN_RESPONSE_EARLY-0.127
- SPERMATOGENESIS-0.104
- COMPLEMENT-0.087
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 93123F83-44EC-4480-9453-F061AA7BC2DB | — | — | 0.899 |
| 2 | A3153235-3128-40AC-9371-AFA1F61E3E59 | — | — | 0.884 |
| 3 | 2535E07B-4CB8-4608-87F3-D8D6371B8862 | — | — | 0.865 |
| 4 | SRR934902 | — | — | 0.861 |
| 5 | 8ACC0F29-A39E-4C1C-A04C-ED6E5FA80C24 | — | — | 0.858 |
| 6 | SRR934719 | — | — | 0.857 |
| 7 | 9970B75F-7AC6-431B-BDBB-120D01582CBE | — | — | 0.854 |
| 8 | SRR934748 | — | — | 0.851 |
| 9 | DD5AA3F8-E3EE-4EDD-8152-B1CC07B70A08 | — | — | 0.844 |
| 10 | 98D004A9-E3F0-448E-BFE2-359F25DF356C | — | — | 0.840 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.549 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.535 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.494 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.475 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.380 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.340 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.334 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.301 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.272 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.268 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.253 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.235 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.224 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.192 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.187 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.167 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.163 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.153 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.150 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.138 | Inavolisib | — uncovered |